Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab + lenvatinib + GEMOX conversion therapy for unresectable extrahepatic biliary carcinoma
ChiCTR2200056808Phase 2Not yet recruiting
- Sponsor
- The First Medical Center of Chinese PLA General Hospital
- Start
- Apr 2022
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab, lenvatinib, gemcitabine and oxaliplatin in cholangiocarcinoma (CCA), sponsored by The First Medical Center of Chinese PLA General Hospital. Primary endpoint: Rate of successful radical resection after conversion therapy. Planned start Apr 2022; status: not yet recruiting.
02
Drugs
tislelizumablenvatinibgemcitabineoxaliplatin
03
Conditions
cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on ChiCTR2200056808.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200056808.